Explore the words cloud of the MMpredict project. It provides you a very rough idea of what is the project "MMpredict" about.
The following table provides information about the project.
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
|Coordinator Country||Netherlands [NL]|
|Total cost||3˙755˙802 €|
|EC max contribution||2˙949˙027 € (79%)|
1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2. (PRIORITY 'Industrial leadership')
|Duration (year-month-day)||from 2016-11-01 to 2020-04-30|
Take a look of project's partnership.
|1||ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM||NL (ROTTERDAM)||coordinator||419˙687.00|
|2||SKYLINEDX B.V.||NL (ROTTERDAM)||participant||1˙882˙475.00|
|3||UNIVERSITA DEGLI STUDI DI TORINO||IT (TORINO)||participant||387˙500.00|
|4||ERASMUS UNIVERSITEIT ROTTERDAM||NL (ROTTERDAM)||participant||210˙615.00|
|5||MYELOMA PATIENTS EUROPE AISBL||BE (Charleroi)||participant||48˙750.00|
The consortium aims to commercialise the MMpredictor as a personalised medicine tool that predicts the most effective treatment strategy for individual Multiple Myeloma (MM) patients. MM is the second most common form of blood cancer contributing to 15% of all blood cancers and ~1,5% and 2% of all cancer deaths annually in the EU and US, respectively. Patients show a large variability in treatment response and side effects due to tumour heterogeneity and the patient’s intrinsic characteristics. Therefore, not every treatment will be suitable for each patient, and treatment strategies are often based on trial-and-error. The availability of multiple (>20) treatment options complicates treatment decision-making even more. With the current development of many more promising treatments, there is an urgent unmet clinical need for a diagnostic assay that supports personalised cancer treatment in order to improve patient health outcomes, prevent side effects and reduce healthcare costs. SkylineDx has previously developed the MMprofiler, a microarray-based diagnostic test that can subtype MM patients and reliably predict MM patient survival (prognosis). In this project, the test’s clinical value will be expanded to include the prediction of treatment effectiveness in individual patients based on Gene Expression Profiling. An addendum for new intended use will be filed to the current in vitro diagnostic (IVD) registration, while renaming the test to MMpredictor. The project will also focus on positioning the test as a cost-effective IVD test for personalised medicine, that will increase health outcome and quality of life of patients and reduce healthcare costs. The consortium consists of a life science SME specialised in molecular diagnostics, clinical centres with world renowned KOLs, a leading health economic institute, and a European MM patient advocacy organisation combining all the required complementary expertise to successfully bring the MMpredictor to market.
Work performed, outcomes and results: advancements report(s)
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MMPREDICT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "MMPREDICT" are provided by the European Opendata Portal: CORDIS opendata.
Development of a monitoring system for inspection of soil and aquifer contamination by shalegas and fracking chemicalsRead More
Tomographic 3D Ultrasound for Safe and More Cost Effective Vascular Diagnostics andTreatment PlanningRead More
Automatic non-destructive recognition of used printing techniques on substratesRead More